Licensing · Global (LMICs) · Announced 29 Sept 2026
Medicines Patent Pool → 11 generic manufacturers
The Medicines Patent Pool has sublicensed Roche's flu antiviral baloxavir to 11 generic makers — including Fidson, Kimia Farma, Hovid, Stellapharm, QCIL and Lekhim — building regional supply for 129 low- and middle-income countries.
Parties: Medicines Patent Pool (under Roche licence) (Switzerland) → 11 generic manufacturers (Fidson, Kimia Farma, Hovid, Stellapharm, QCIL, Lekhim, Laurus Labs, MSN, Desano, Guilin Pharma, Biolab)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- 129 low- and middle-income countries
- Therapeutic area
- Infectious Disease
- Asset
- Baloxavir marboxil — single-dose influenza antiviral; generic sublicences covering 129 low- and middle-income countries
- Announced
- 29 Sept 2026
Our analysis
Why this matters
The Medicines Patent Pool (MPP) has signed sublicences with 11 generic manufacturers to make baloxavir marboxil, Roche's single-dose influenza antiviral, under the voluntary licence Roche granted MPP in May 2026. The licence covers 129 countries, subject to local regulatory approval.
The list is notable for who is on it. Alongside four global generics players, MPP chose seven regional manufacturers — in Nigeria, Uganda, Indonesia, Malaysia, Vietnam, Ukraine and Brazil — explicitly to build regional supply for pandemic preparedness. For several of them, this is their first sublicence for a modern antiviral and a step up in technical capability.
The full analysis is free to read with a work email on this page.
Source: Health Policy Watch